CANCER GENETICS, INC 4
4 · CANCER GENETICS, INC · Filed May 25, 2017
Insider Transaction Report
Form 4
Gitelman Igor
Chief Accounting Officer
Transactions
- Sale
Common Stock, par value $0.0001 per share
2017-05-23$4.02/sh−937$3,763→ 0 total - Purchase
Common Stock, par value $0.0001 per share
2017-05-25$3.95/sh+937$3,701→ 937 total - Exercise/Conversion
Stock Option (right to buy)
2017-05-23−937→ 14,063 totalExercise: $2.50Exp: 2027-02-22→ Common Stock, par value $0.0001 per share (937 underlying) - Exercise/Conversion
Common Stock, par value $0.0001 per share
2017-05-23$2.50/sh+937$2,343→ 937 total
Footnotes (2)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.025 to $4.01, inclusive. The reporting person undertakes to provide Cancer Genetics, Inc., any security holder of Cancer Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4.
- [F2]The shares underlying the option shall vest in 48 equal monthly installments commencing on the date of grant until fully vested, provided that the reporting person remains a service provider to Cancer Genetics, Inc. through each applicable vesting period.